Terms: = Lung cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
425 results:
1. Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract] [Full Text] [Related]
2. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
3. The atr inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL; Sanseviero E; Karmokar A; Taylor D; Milo M; Michaloglou C; Hughes A; Mai M; King M; Solanki A; Magiera L; Miragaia R; Kar G; Standifer N; Surace M; Gill S; Peter A; Talbot S; Tohumeken S; Fryer H; Mostafa A; Mulgrew K; Lam C; Hoffmann S; Sutton D; Carnevalli L; Calero-Nieto FJ; Jones GN; Pierce AJ; Wilson Z; Campbell D; Nyoni L; Martins CP; Baker T; Serrano de Almeida G; Ramlaoui Z; Bidar A; Phillips B; Boland J; Iyer S; Barrett JC; Loembé AB; Fuchs SY; Duvvuri U; Lou PJ; Nance MA; Gomez Roca CA; Cadogan E; Critichlow SE; Fawell S; Cobbold M; Dean E; Valge-Archer V; Lau A; Gabrilovich DI; Barry ST
Nat Commun; 2024 Feb; 15(1):1700. PubMed ID: 38402224
[TBL] [Abstract] [Full Text] [Related]
4. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
5. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
Guo C; Liu Y; Yang H; Xia Y; Li X; Chen L; Feng Y; Zhang Y; Chen Y; Huang Z
Br J Radiol; 2024 Mar; 97(1156):859-867. PubMed ID: 38290775
[TBL] [Abstract] [Full Text] [Related]
6. NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the atr-CHK1 signaling pathway.
Sun X; Dong M; Li J; Sun Y; Gao Y; Wang Y; Du L; Liu Y; Ji K; He N; Wang J; Zhang M; Song H; Xu C; Liu Q
Theranostics; 2024; 14(2):681-698. PubMed ID: 38169561
[No Abstract] [Full Text] [Related]
7. [Work Participation after Multimodal Rehabilitation due to cancer: Representative Analyses using Routine Data of the German Pension Insurance].
Fauser D; Zollmann P; Streibelt M; Bethge M
Rehabilitation (Stuttg); 2024 Apr; 63(2):107-118. PubMed ID: 38065547
[TBL] [Abstract] [Full Text] [Related]
8. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/atr-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
[TBL] [Abstract] [Full Text] [Related]
9. The association of genetic factors with serum calretinin levels in asbestos-related diseases.
Zupanc C; Franko A; Strbac D; Kovac V; Dolzan V; Goricar K
Radiol Oncol; 2023 Dec; 57(4):473-486. PubMed ID: 38038422
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract] [Full Text] [Related]
11. Copy number loss of KDM5D may be a predictive biomarker for atr inhibitor treatment in male patients with pulmonary squamous cell carcinoma.
Ura A; Hayashi T; Komura K; Hosoya M; Takamochi K; Sato E; Saito S; Wakai S; Handa T; Saito T; Kato S; Suzuki K; Yao T;
J Pathol Clin Res; 2024 Jan; 10(1):e350. PubMed ID: 37974379
[TBL] [Abstract] [Full Text] [Related]
12. Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals.
Ren J; Wang Y; Liu C; Yang L; Men X; Qiu Z
Eur J Med Res; 2023 Nov; 28(1):478. PubMed ID: 37924162
[TBL] [Abstract] [Full Text] [Related]
13. New horizons in lung cancer management through atr/CHK1 pathway modulation.
Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
[TBL] [Abstract] [Full Text] [Related]
14. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract] [Full Text] [Related]
15. Effects of Combined Therapeutic Targeting of AXL and atr on Pleural Mesothelioma Cells.
Hirai S; Yamada T; Katayama Y; Ishida M; Kawachi H; Matsui Y; Nakamura R; Morimoto K; Horinaka M; Sakai T; Sekido Y; Tokuda S; Takayama K
Mol Cancer Ther; 2024 Feb; 23(2):212-222. PubMed ID: 37802502
[TBL] [Abstract] [Full Text] [Related]
16. Long Noncoding RNA ZBED5-AS1 Facilitates Tumor Progression and Metastasis in lung Adenocarcinoma via ZNF146/atr/Chk1 Axis.
Jiang F; Huang X; Ling L; Tang S; Zhou H; Cai X; Wang Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762228
[TBL] [Abstract] [Full Text] [Related]
17. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review.
Chen J; Chen S; Luo H; Long S; Yang X; He W; Wu W; Wang S
Int Immunopharmacol; 2023 Nov; 124(Pt B):110919. PubMed ID: 37722262
[TBL] [Abstract] [Full Text] [Related]
18. Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Yadav KS; Raut HC; Nijhawan HP
Pharm Dev Technol; 2023 Oct; 28(8):755-767. PubMed ID: 37665569
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes of lung oligometastasis in pancreatic cancer.
Takeda T; Sasaki T; Ichinose J; Inoue Y; Okamoto T; Mie T; Furukawa T; Kasuga A; Oba A; Matsuura Y; Nakao M; Ozaka M; Mun M; Takahashi Y; Sasahira N
Jpn J Clin Oncol; 2023 Dec; 53(12):1144-1152. PubMed ID: 37609670
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
[Next]
